LPCN Lipocine Inc Total Asset Value of Company

LPCN (Lipocine Corp) - company brandmark

The market dynamics of Lipocine Inc. (LPCN) on the GURU.Markets platform show total assets at 21.20. Lipocine Inc. (LPCN) relies on the capacities of CDMO partners for drug production while maintaining its R&D centers in Utah. Top-tier biochemists are drawn by the prospects of an innovative drug delivery method, yet heavy investments in steatohepatitis therapy and uncertainty regarding clinical trial outcomes are exerting significant financial pressure on the business.

LPCN (Lipocine Inc.) Company Total Assets history from 07/04/2022 to 10/30/2026

Analytical breakdowns and data insights for company Lipocine Corp (LPCN)

- stock quotes and analyst forecast:
Share Price lipocine.com|LPCN - Price Target Chart
- market capitalization data:
Market Valuation Lipocine Corporation|LPCN - Enterprise Value
- issuer book value statistics:
Accounting Value of a Share Lipocine|LPCN - Book Capitalization|Market Capitalization to Book Value Ratio lipocine.com|LPCN - Aggregate Company Assets
- debt burden and liquidity indicators:
All Debt to Shareholders' Equity Ratio Lipocine Inc.|LPCN - Long-Term Debt to Equity|Short-Term Debt to Equity Ratio Lipocine Corporation|LPCN - Company Aggregate Debts|Debts to Book Capitalization Lipocine Corporation|LPCN - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings Lipocine|Quick Liquidity Indicator lipocine.com
- net income and valuation multiples indicators:
LPCN - Net Profit
Fundamental valuation:Lipocine Inc.
Manufactured products of Lipocine Inc.

Total assets represent the aggregate value of a company's resources, calculated reversely via ROA as the sum of liabilities and equity. The total assets trend on GURU.Markets reflects the financial strength of Lipocine Inc. (LPCN), where the value of intellectual property and patents for drug delivery systems plays a key role, shielding the company from direct price competition in the endocrine sector.

Key competitors

Total Business Assets ASND|Aggregate Company Assets Madrigal Pharmaceuticals, Inc.|Corcept Therapeutics Inc. - Total Asset Value of Company|Company Total Assets RYTM|AKRO (Akero Corp) - Aggregate Asset Value|Company Total Assets MTSR (Metsera Inc)|Company Total Assets moonlaketx.com MLTX|CRNX - Aggregate Company Assets|Aggregate Asset Value NAMS (NewAmsterdam Pharma Company)|Soleno (SLNO) - Aggregate Company Assets|Cumulative Company Assets Amicus Corp|ETNB (89bio, Inc.) - Company Total Assets|Company Total Assets agios.com|Cumulative Company Assets GPCR (Structure Therapeutics Inc.)|MDXG (MiMedx Group Inc) - Aggregate Asset Value|Aggregate Company Assets Rezolute Corp RZLT|LXRX - Cumulative Company Assets|MBX Biosciences Inc - Company Total Assets|Company Assets altimmune.com|AARD (Aardvark Therapeutics) - Cumulative Company Assets|SGMT: Aggregate Business Assets|BIOA (BioAge Labs Inc.) - Company Total Assets|Company Total Assets Biomea Fusion Corp|Company Total Assets QNCX|Aggregate Company Assets GUTS (fractyl.com)|Aggregate Company Assets vTv Therapeutics VTVT|Agape ATP Corp (ATPC) - Company Assets|PLUR - Aggregate Company Assets|SYBX: Aggregate Company Assets|MTNB: Company Total Assets|SPRB - Company Total Asset Base|Aggregate Company Assets Galecto|Carmell Corp. (CTCX) - Company Total Asset Base|Aggregate Company Assets Lumos Pharma Corp (LUMO)|Cumulative Company Assets Organovo Corp ONVO|Aggregate Company Assets Radius Recycling, Inc. RDUS